OverviewSuggest Edit

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. The Company's research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s capacity for cellular growth and repair. The Company’s lead product candidate, luspatercept, is being evaluated in two Phase 3 studies in a global partnership with Celgene to treat chronic, sometimes debilitating anemias in myelodysplastic syndromes (MDS) and beta-thalassemia. Acceleron is also advancing clinical programs in neuromuscular disorders and cancer, and preclinical research in fibrotic and other diseases.

... Show more
TypePublic
Founded2003
HQCambridge, US
Websiteacceleronpharma.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Feb 2019)139
Job Openings22
Revenue (FY, 2017)$13.5 M(-51%)
Share Price (Feb 2019)$42.4 (-2%)

Key People/Management at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

CFO
Steven Ertel

Steven Ertel

COO
Matthew Sherman

Matthew Sherman

Chief Medical Officer
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
John Quisel

John Quisel

SVP, Business Development and General Councel
Show more

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, US (HQ)
128 Sidney Street
Show all (1)
Report incorrect company information

Acceleron Pharma Financials and Metrics

Acceleron Pharma Revenue

Acceleron Pharma's revenue was reported to be $13.48 m in FY, 2017
USD

Revenue (Q3, 2018)

3.3m

Net income (Q3, 2018)

(29.0m)

EBIT (Q3, 2018)

(30.1m)

Market capitalization (13-Feb-2019)

2.0b

Closing stock price (13-Feb-2019)

42.4

Cash (30-Sep-2018)

112.4m
Acceleron Pharma's current market capitalization is $2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

57.2m14.6m18.1m27.8m13.5m

Revenue growth, %

(74%)24%53%

General and administrative expense

14.2m20.6m25.3m33.7m

R&D expense

36.1m58.4m68.6m89.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

4.3m3.3m5.7m4.2m18.2m3.2m3.0m3.7m3.1m3.0m3.2m3.7m3.3m

General and administrative expense

3.0m3.8m4.7m5.4m5.9m6.7m6.4m7.8m11.4m7.5m7.4m7.7m8.7m

R&D expense

8.1m11.8m14.2m13.3m16.2m16.1m17.1m21.7m21.6m21.1m23.4m25.9m24.7m

Operating expense total

11.2m15.5m18.8m18.8m22.2m22.9m23.5m29.6m33.0m28.6m30.9m33.6m33.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

113.2m176.5m27.8m21.0m100.2m

Accounts Receivable

11.5m

Inventories

2.2m2.5m2.5m3.9m

Current Assets

119.0m182.3m110.9m146.8m285.2m
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.9m)(51.3m)(63.9m)(57.0m)(108.5m)

Depreciation and Amortization

915.0k1.1m1.2m1.7m2.8m

Inventories

(823.0k)(255.0k)7.0k(1.4m)

Accounts Payable

(53.0k)(161.0k)151.0k644.0k(504.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(9.1m)(10.4m)(11.9m)5.1m(17.0m)(37.7m)(25.4m)(55.1m)(80.5m)(26.2m)(55.2m)(84.1m)

Depreciation and Amortization

265.0k324.0k715.0k1.2m541.0k1.2m2.0m904.0k1.9m2.9m

Accounts Payable

891.0k1.4m2.6m3.3m1.6m1.8m2.6m(42.0k)(309.0k)1.2m(778.0k)71.0k(566.0k)591.0k183.0k80.0k

Cash From Operating Activities

(12.5m)(14.9m)(28.0m)(39.1m)(55.9m)(23.4m)(45.6m)(65.7m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Phase III Trials Products

2 2
Show all operating metrics
Report incorrect company information

Acceleron Pharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Acceleron Pharma News and Updates

Key Findings of the Growth/Differentiation Factor 8 Market | Acceleron Pharma, Inc., Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company

HTF MI published a new industry research that focuses on Growth/Differentiation Factor 8 market and delivers in-depth market analysis and future prospects of Global Growth/Differentiation Factor 8 market. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Acceleron Pharma Blogs

Acceleron Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 16, 2019-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced

Acceleron Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 14, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it

Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2019-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2

Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference Content Import Wed, 01/02/2019 - 07:03 Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference Jan 02, 2019 This release is a backfill from a …

Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 5, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias,

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session

Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J.
Show more

Acceleron Pharma Company Life and Culture

Report incorrect company information

Acceleron Pharma Frequently Asked Questions

  • When was Acceleron Pharma founded?

    Acceleron Pharma was founded in 2003.

  • Who are Acceleron Pharma key executives?

    Acceleron Pharma's key executives are Habib Dable, Kevin McLaughlin and Steven Ertel.

  • How many employees does Acceleron Pharma have?

    Acceleron Pharma has 139 employees.

  • What is Acceleron Pharma revenue?

    Latest Acceleron Pharma annual revenue is $13.5 m.

  • What is Acceleron Pharma revenue per employee?

    Latest Acceleron Pharma revenue per employee is $97 k.

  • Who are Acceleron Pharma competitors?

    Competitors of Acceleron Pharma include Roche, XOMA and Minerva Neurosciences.

  • Where is Acceleron Pharma headquarters?

    Acceleron Pharma headquarters is located at 128 Sidney Street, Cambridge.

  • Where are Acceleron Pharma offices?

    Acceleron Pharma has an office in Cambridge.

  • How many offices does Acceleron Pharma have?

    Acceleron Pharma has 1 office.